Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T12:55:28.641Z.
Calculation as of: 2026-10-06T12:55:28.641Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3a5f53e60080e4c0bd8028294acadec9828b96594dd07725d589d3e2217ece04
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Allogene Therapeutics, Inc.
Market Cap
$517.73M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$517.79M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$519.25M
Operating Cash Flow Yield
N/A
TTM Avg
536.71%
3Y Avg
536.71%
5Y Avg
536.71%
Market Cap
$491.55M
Operating Cash Flow Yield
4.49%
TTM Avg
5.09%
3Y Avg
4.22%
5Y Avg
4.07%
Market Cap
$547.86M
Operating Cash Flow Yield
3.58%
TTM Avg
3.98%
3Y Avg
3.57%
5Y Avg
3.57%
Market Cap
$487.30M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$551.09M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$481.33M
Operating Cash Flow Yield
N/A
TTM Avg
18.97%
3Y Avg
18.89%
5Y Avg
14.32%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $517.73M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | 536.71% | 536.71% | 536.71% |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | 4.49% | 5.09% | 4.22% | 4.07% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 3.58% | 3.98% | 3.57% | 3.57% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $481.33M | N/A | 18.97% | 18.89% | 14.32% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 4.04% | 4.04% | 4.04% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
